Yissum - Research Development Company of the Hebrew University

New Target for the Treatment of Abdominal Obesity

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

New target for the treatment of obesity and abdominal obesity by inhibiting the FGFR3 receptor signalling pathway
Project ID : 7-2018-4658

Description of the technology


Metabolic diseases


Abdominal obesity, obesity

Current development stage

Pharmaceutical development: TRL2Hypothesis Formulated

Collaboration Opportunity

Sponsored Research with an option to License Research Results


Obesity is the leading cause of death in America, and is associated with an increase in chronic diseases like, cardiovascular diseases, hypertension, and metabolic disease involving the liver as well as type 2 diabetes. A recent study has shown a correlation between an overexpression of a specific protein and abdominal obesity, however no follow up studies were carried out to indicate a treatment.

Our Innovation

The researcher has identified several inhibitory small molecules that specifically target the overexpressed protein responsible for abdominal obesity. A small molecule therapy would inhibit the proteins and reduce or prevent abdominal obesity.


The researcher is looking for sponsored research funding from a partner to:

  • Identify the best small molecule for inhibiting the overexpressed proteins.
  • Conduct an in vitro study to elucidate the influence of the small molecule on signaling pathways responsible for abdominal obesity.
  • Conduct an in vivo study developed in the researcher’s lab to see the influences of the small molecule on the model animal.
  • Conduct an analysis of the carcass of the model animals.

Project manager

Ilya Pittel

Project researchers

Efrat Monsonego-Ornan
HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences
Biochemistry, Food Science and Nutrition

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.